|
0
|
7
|
8fvlL |
Pcsk9 in complex with an inhibitor |
|
0
|
13
|
8fpqL |
Pcsk9 in complex with an inhibitor |
|
20
|
92
|
8fvpA |
Pcsk9 in complex with an inhibitor |
|
91
|
360
|
8w10A |
Plasmodium vivax pmx-mk7602 inhibitor complex |
|
83
|
305
|
8ue0A |
Crystal structure of sars-cov-2 3cl protease with inhibitor 47 |
|
84
|
302
|
8udfA |
Crystal structure of sars-cov-2 3cl protease with inhibitor del_7 |
|
81
|
304
|
8uebA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 30 |
|
84
|
302
|
8uefA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 32 |
|
82
|
304
|
8udxA |
Crystal structure of sars-cov-2 3cl protease with c145 sulfinic acid in complex with inhibitor 17 |
|
86
|
304
|
8uehA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 31 |
|
82
|
304
|
8uegA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 27 |
|
87
|
306
|
8udmA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 16 |
|
82
|
302
|
8ueaA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 29 |
|
85
|
301
|
8udyA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 25 |
|
83
|
301
|
8udwA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 2 |
|
86
|
302
|
8udqA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 1 |
|
87
|
305
|
8udpA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 14 |
|
83
|
302
|
8udjA |
Crystal structure of sars-cov-2 3cl protease with inhibitor del_2 |
|
86
|
305
|
8udoA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 15 |
|
85
|
304
|
8ueiA |
Crystal structure of sars-cov-2 3cl protease with inhibitor 28 |
|
164
|
464
|
9nnoA |
Crystal structure of cyp46a1 with n-[6-(1,3-oxazol-5-yl)-4-(trifluoromethyl)pyridin-2-yl]cyclopropanecarboxamide (compound 4l) |
|
68
|
227
|
9o0wA |
Co-crystal structure of human trex1 in complex with an inhibitor |
|
69
|
230
|
9o0yA |
Co-crystal structure of human trex1 in complex with an inhibitor |
|
67
|
228
|
9o0xA |
Co-crystal structure of human trex1 in complex with an inhibitor |
|
161
|
465
|
9nnmA |
Crystal structure of cyp46a1 with 3-chloro-n-[(3m)-3-(1,3-oxazol-5-yl)-5-(trifluoromethyl)phenyl]benzamide (compound 3f) |
|
164
|
464
|
9nnjA |
Crystal structure of cyp46a1 with 3-chloro-n-[(3m)-3-(1,3-oxazol-5-yl)phenyl]-n-(propan-2-yl)benzene-1-sulfonamide (compound 2) |
|
51
|
148
|
9bu4A |
Crystal structure of an mkp5 mutant, y435w, in complex with an allosteric inhibitor |
|
0
|
5
|
8vdvL |
Pcsk9 in complex with inhibitor |
|
140
|
529
|
8vdvB |
Pcsk9 in complex with inhibitor |
|
21
|
92
|
8vdvA |
Pcsk9 in complex with inhibitor |
|
46
|
147
|
9q7xA |
Crystal structure of the mkp5 loop mutant n448a in complex with the allosteric inhibitor |
|
51
|
148
|
9ok9A |
Crystal structure of an mkp5 allosteric loop mutant, p447v, in complex with an allosteric inhibitor |
|
51
|
148
|
9o8wA |
Crystal structure of an mkp5 mutant, y435f, in complex with an allosteric inhibitor |
|
166
|
464
|
9nniA |
Crystal structure of cyp46a1 with cyclopropyl[(4m)-4-(1,3-oxazol-5-yl)-6-(trifluoromethyl)-1h-indol-1-yl]methanone (compound 2b) |
|
165
|
462
|
9nnaA |
Crystal structure of cyp46a1 with [(1r,5s)-3-oxa-8-azabicyclo[3.2.1]octan-8-yl][(4r,8m)-8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methanone (compound 3k) |
|
52
|
148
|
9nsbA |
Crystal structure of an mkp5 allosteric loop mutant, s446g, in complex with an allosteric inhibitor |
|
165
|
464
|
9nneA |
Crystal structure of cyp46a1 with (morpholin-4-yl)[(4r,8m)-8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methanone (compound 2h) |
|
84
|
296
|
9kgqA |
Discovery of an orally bioavailable reversible covalent sars-cov-2 mpro inhibitor with pan-coronavirus activity |
|
81
|
299
|
9kgnA |
Discovery of an orally bioavailable reversible covalent sars-cov-2 mpro inhibitor with pan-coronavirus activity |
|
83
|
302
|
9kgsA |
Discovery of an orally bioavailable reversible covalent sars-cov-2 mpro inhibitor with pan-coronavirus activity |
|
92
|
307
|
9kgrA |
Discovery of an orally bioavailable reversible covalent sars-cov-2 mpro inhibitor with pan-coronavirus activity |
|
86
|
301
|
9cjuA |
Structure of sars-cov-2 main protease in complex with bofutrelvir in orthorhombic form |
|
83
|
301
|
9cjtA |
X-ray crystal structure of sars-cov-2 main protease quadruple mutants in complex with bofutrelvir |
|
83
|
303
|
9cjvA |
X-ray crystal structure of sars-cov-2 main protease complex with bofutrelvir |
|
83
|
303
|
9cjpA |
X-ray crystal structure of sars-cov-2 main protease quadruple mutants in complex with nirmatrelvir |
|
83
|
301
|
9cjsA |
X-ray crystal structure of sars-cov-2 main protease triple mutants in complex with bofutrelvir |
|
84
|
305
|
9cjqA |
X-ray crystal structure of sars-cov-2 main protease quadruple mutants in complex with ensitrelvir |
|
86
|
300
|
9cjrA |
X-ray crystal structure of sars-cov-2 main protease double mutants in complex with ensitrelvir |
|
107
|
380
|
8v4xA |
Structure of malt1 in complex with an allosteric inhibitor |
|
94
|
291
|
8izcA |
Human ck1 delta kinase structure bound to inhibitor |
